NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 4, 2016, Pages 389-400

  Anderson, Kenneth C ^a   Alsina, Melissa ^b   Atanackovic, Djordje ^c   Biermann, J Sybil ^d   Chandler, Jason C ^e   Costello, Caitlin ^f   Djulbegovic, Benjamin ^b   Fung, Henry C ^g   Gasparetto, Cristina ^h   Godby, Kelly ⁱ   Hofmeister, Craig ^j   Holmberg, Leona ^k   Holstein, Sarah ^l   Huff, Carol Ann ^m   Kassim, Adetola ⁿ   Krishnan, Amrita Y ^o   Kumar, Shaji K ^p   Liedtke, Michaela ^q   Lunning, Matthew ^r   Raje, Noopur ^s   Reu, Frederic J ^t   Singhal, Seema ^u   Somlo, George ^o   Stockerl Goldstein, Keith ^v   Treon, Steven P ^a   Weber, Donna ^w   Yahalom, Joachim ^x   Shead, Dorothy A ^y   Kumar, Rashmi ^y   more..

^a Dana Farber Brigham and Women's Cancer Center   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k SEATTLE CANCER CARE ALLIANCE   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ VANDERBILT INGRAM CANCER CENTER   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p MAYO CLINIC CANCER CENTER   (United States)

^q STANFORD CANCER INSTITUTE   (United States)

^r UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^t UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^u NORTHWESTERN UNIVERSITY   (United States)

^v BARNES JEWISH HOSPITAL   (United States)

^w UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^x MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^y National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; IXAZOMIB; LENALIDOMIDE; PANOBINOSTAT; POMALIDOMIDE;

ACCREDITATION; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTINUING EDUCATION; HUMAN; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE;

HUMANS; MULTIPLE MYELOMA;

EID: 84964408701     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0046     Document Type: Article

References (37)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-548.
3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
5. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863-2869.
6. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-686.
7. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712-2717.
8. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-4382.
9. Durie B, Hoering A, Rajkumar S V, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [abstract]. Blood 2015;126:25.
10. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337-1341.
11. Einsele H, Liebisch P, Langer C, et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract]. Blood 2009;114: Abstract 131.
12. Reeder CB, Reece DE, Kukreti V, et al. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 2014;167:563-565.
13. Reeder CB, Reece DE, Kukreti V, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416-3417.
14. Jimenez-Zepeda VH, Duggan P, Neri PE, Bahlis NJ. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients [abstract]. Blood 2014;124; 5751.
15. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503-1512.
16. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-1809.
17. Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 2014;99:e162-164.
18. Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed Multiple Myeloma (MM) patients [abstract]. Blood 2012;120: Abstract 732.
19. Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [abstract]. Blood 2013;122: Abstract 538.
20. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17:27-38.
21. Lokhorst HM, Plesner T, Laubach J P, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207-1219.
22. Lonial S, Weiss B, Usmani S, et al. Phase II study of daratumumab (DARA) monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma (MM):54767414MMY2002 (Sirius) [abstract]. J Clin Oncol 2015;33(15 Suppl): Abstract LBA8512.
23. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-2784.
24. Lonial S, Dimopoulos MA, Palumbo A, et al. ELOQUENT-2: a phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol 2015;33(Suppl): Abstract 8508.
25. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 TOURMALINE-MM1 study. Blood 2015;126:727-727.
26. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014;124:1047-1055.
27. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 2014;124:1038-1046.
28. Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338.
29. Kumar SK, Laplant BR, Reeder CB, et al. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood 2015;126:3050-3050.
30. Dimopoulos MA, Palumbo A, Weisel K, et al. Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Presented at the American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco, California. Abstract 80.
31. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, openlabel, phase 3 trial. Lancet Oncol 2013;14:1055-1066.
32. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280:233-241.
33. San-Miguel J F, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195-1206.
34. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122:2331-2337.
35. Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 2016;127:713-721.
36. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 2015;100:670-676.
37. Berdeja JG, Gregory TK, Matous J, et al. A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM) [Abstract]. J Clin Oncol 2015;33(Suppl): Abstract 8513.